ABSCI CORP Selling, General and Administrative Expense
ABSCI CORP (ABSI) reported Selling, General and Administrative Expense of $9.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- ABSCI CORP selling, general and administrative expense for the quarter ending 2026-06-30 was $9.16M, a 7.46% increase year-over-year.
- ABSCI CORP selling, general and administrative expense for the quarter ending 2026-03-31 was $9.06M, a 4.37% decline year-over-year.
- ABSCI CORP selling, general and administrative expense for the quarter ending 2025-12-31 was $8.62M, a 2.39% decline year-over-year.
- ABSCI CORP selling, general and administrative expense for the quarter ending 2025-09-30 was $8.44M, a 8.81% decline year-over-year.
- ABSCI CORP selling, general and administrative expense for fiscal 2025 was $35.06M, a 3.09% decline from fiscal 2024.
- ABSCI CORP selling, general and administrative expense for fiscal 2024 was $36.17M, a 4.38% decline from fiscal 2023.
- ABSCI CORP selling, general and administrative expense for fiscal 2023 was $37.83M, a 6.71% decline from fiscal 2022.
- ABSCI CORP selling, general and administrative expense for fiscal 2022 was $40.55M, a 40.90% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.16M 10-Q · filed 2026-08-11 | $18.22M 10-Q · filed 2026-08-11 | $26.84M derived: sum of 3 quarters · filed 2026-08-11 | $35.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $9.06M 10-Q · filed 2026-05-07 | $17.68M derived: sum of 2 quarters · filed 2026-05-07 | $26.12M derived: sum of 3 quarters · filed 2026-05-07 | $34.64M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $8.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $17.06M derived: sum of 2 quarters · filed 2026-03-24 | $25.59M derived: sum of 3 quarters · filed 2026-08-11 | $35.06M 10-K · filed 2026-03-24 |
| 2025-09-30 | $8.44M 10-Q · filed 2025-11-12 | $16.97M derived: sum of 2 quarters · filed 2026-08-11 | $26.44M 10-Q · filed 2025-11-12 | $35.27M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $8.53M 10-Q · filed 2026-08-11 | $18.00M 10-Q · filed 2026-08-11 | $26.83M derived: sum of 3 quarters · filed 2026-08-11 | $36.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $9.47M 10-Q · filed 2026-05-07 | $18.30M derived: sum of 2 quarters · filed 2026-05-07 | $27.56M derived: sum of 3 quarters · filed 2026-05-07 | $36.90M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $18.08M derived: sum of 2 quarters · filed 2026-03-24 | $27.43M derived: sum of 3 quarters · filed 2026-03-24 | $36.17M 10-K · filed 2026-03-24 |
| 2024-09-30 | $9.26M 10-Q · filed 2025-11-12 | $18.60M derived: sum of 2 quarters · filed 2025-11-12 | $27.35M 10-Q · filed 2025-11-12 | $36.67M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $9.35M 10-Q · filed 2025-08-12 | $18.09M 10-Q · filed 2025-08-12 | $27.41M derived: sum of 3 quarters · filed 2025-08-12 | $36.92M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $8.74M 10-Q · filed 2025-05-13 | $18.07M derived: sum of 2 quarters · filed 2025-05-13 | $27.57M derived: sum of 3 quarters · filed 2025-05-13 | $36.98M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $18.83M derived: sum of 2 quarters · filed 2025-03-18 | $28.24M derived: sum of 3 quarters · filed 2025-03-18 | $37.83M 10-K · filed 2025-03-18 |
| 2023-09-30 | $9.51M 10-Q · filed 2024-11-12 | $18.91M derived: sum of 2 quarters · filed 2024-11-12 | $28.51M 10-Q · filed 2024-11-12 | $36.26M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $9.41M 10-Q · filed 2024-08-14 | $19.00M 10-Q · filed 2024-08-14 | $26.75M derived: sum of 3 quarters · filed 2024-08-14 | $38.16M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $9.59M 10-Q · filed 2024-05-14 | $17.34M derived: sum of 2 quarters · filed 2024-05-14 | $28.75M derived: sum of 3 quarters · filed 2024-05-14 | $39.26M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $19.16M derived: sum of 2 quarters · filed 2024-03-21 | $29.66M derived: sum of 3 quarters · filed 2024-03-21 | $40.55M 10-K · filed 2024-03-21 |
| 2022-09-30 | $11.41M 10-Q · filed 2023-11-14 | $21.91M derived: sum of 2 quarters · filed 2023-11-14 | $32.80M 10-Q · filed 2023-11-14 | $41.99M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $10.51M 10-Q · filed 2023-08-14 | $21.40M 10-Q · filed 2023-08-14 | $30.58M derived: sum of 3 quarters · filed 2023-08-14 | $40.31M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $10.89M 10-Q · filed 2023-05-15 | $20.07M derived: sum of 2 quarters · filed 2023-05-15 | $29.80M derived: sum of 3 quarters · filed 2023-05-15 | $34.98M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $18.92M derived: sum of 2 quarters · filed 2023-03-30 | $24.09M derived: sum of 3 quarters · filed 2023-03-30 | $28.78M 10-K · filed 2023-03-30 |
| 2021-09-30 | $9.73M 10-Q · filed 2022-11-09 | $14.91M derived: sum of 2 quarters · filed 2022-11-09 | $19.60M 10-Q · filed 2022-11-09 | $22.01M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $5.18M 10-Q · filed 2022-08-11 | $9.86M 10-Q · filed 2022-08-11 | $12.28M derived: sum of 3 quarters · filed 2022-08-11 | $13.53M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.68M 10-Q · filed 2022-05-11 | $7.10M derived: sum of 2 quarters · filed 2022-05-11 | $8.36M derived: sum of 3 quarters · filed 2022-05-11 | $9.22M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $3.67M derived: sum of 2 quarters · filed 2022-03-22 | $4.53M derived: sum of 3 quarters · filed 2022-03-22 | $5.50M 10-K · filed 2022-03-22 |
| 2020-09-30 | $1.26M 10-Q · filed 2021-11-09 | $2.12M derived: sum of 2 quarters · filed 2021-11-09 | $3.09M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $861.00K 10-Q · filed 2021-09-07 | $1.83M 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |